Acadia Pharmaceuticals (ACAD) Net Equity Issued and Repurchased (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Net Equity Issued and Repurchased of $4.2 million for Q1 2026, up 130.2% year-over-year from $1.8 million in Q1 2025, and down 81.33% quarter-over-quarter from $22.7 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 130.2% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $52.3 million (up 584.24% YoY), while the FY2025 annual figure was $49.9 million, up 628.75% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $4.2 million, down from $22.7 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $22.7 million in Q4 2025, with the low at $268000.0 in Q3 2024.
- The 5-year median for Net Equity Issued and Repurchased is $3.6 million (2024), against an average of $5.5 million.
- The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased jumped 4342.86% in 2023, then sank 97.9% in 2024.
- Acadia Pharmaceuticals' Net Equity Issued and Repurchased stood at $1.6 million in 2022, then jumped by 236.68% to $5.4 million in 2023, then plunged by 63.77% to $2.0 million in 2024, then surged by 1051.14% to $22.7 million in 2025, then plunged by 81.33% to $4.2 million in 2026.
- Business Quant data shows ACAD's Net Equity Issued and Repurchased at $4.2 million in Q1 2026, $22.7 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 10.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.49 Mn |
| Jun 30, 2026 | 10.49 Mn |
| Mar 31, 2026 | 4.23 Mn |
| Mar 31, 2026 | 4.23 Mn |
| Dec 31, 2025 | 22.67 Mn |
| Dec 31, 2025 | 22.67 Mn |
| Sep 30, 2025 | 9.42 Mn |
| Sep 30, 2025 | 9.42 Mn |
| Jun 30, 2025 | 15.96 Mn |
| Jun 30, 2025 | 15.96 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Dec 31, 2024 | 1.97 Mn |
| Sep 30, 2024 | 268,000.00 |
| Sep 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 3.57 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |